AR036303A1 - Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion para el tratamiento de la enfermedad de parkinson - Google Patents
Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion para el tratamiento de la enfermedad de parkinsonInfo
- Publication number
- AR036303A1 AR036303A1 ARP020103212A ARP020103212A AR036303A1 AR 036303 A1 AR036303 A1 AR 036303A1 AR P020103212 A ARP020103212 A AR P020103212A AR P020103212 A ARP020103212 A AR P020103212A AR 036303 A1 AR036303 A1 AR 036303A1
- Authority
- AR
- Argentina
- Prior art keywords
- parkinson
- brain
- association
- disease
- treatment
- Prior art date
Links
- 210000004556 brain Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 229940124802 CB1 antagonist Drugs 0.000 abstract 1
- 150000001539 azetidines Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0111201A FR2829027A1 (fr) | 2001-08-29 | 2001-08-29 | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036303A1 true AR036303A1 (es) | 2004-08-25 |
Family
ID=8866793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103212A AR036303A1 (es) | 2001-08-29 | 2002-08-27 | Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion para el tratamiento de la enfermedad de parkinson |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7105504B2 (enExample) |
| EP (1) | EP1423146A1 (enExample) |
| JP (1) | JP2005505539A (enExample) |
| AR (1) | AR036303A1 (enExample) |
| CA (1) | CA2458855A1 (enExample) |
| FR (1) | FR2829027A1 (enExample) |
| IL (1) | IL160558A0 (enExample) |
| MX (1) | MXPA04001848A (enExample) |
| WO (1) | WO2003018060A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| KR20060019587A (ko) | 2003-06-11 | 2006-03-03 | 머크 앤드 캄파니 인코포레이티드 | 치환된 3-알킬 및 3-알케닐 아제티딘 유도체 |
| EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| KR20090057349A (ko) * | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파／칼비도파의 ２４시간의 장기간 장내투여 |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| EP2114933B1 (en) | 2007-01-04 | 2011-09-07 | Prosidion Ltd | Piperidine gpcr agonists |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177593A1 (en) * | 1998-09-30 | 2002-11-28 | Yuji Ishihara | Agents and crystals for improving excretory potency of urinary bladder |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
-
2001
- 2001-08-29 FR FR0111201A patent/FR2829027A1/fr active Pending
-
2002
- 2002-08-27 AR ARP020103212A patent/AR036303A1/es not_active Application Discontinuation
- 2002-08-28 JP JP2003522575A patent/JP2005505539A/ja not_active Abandoned
- 2002-08-28 MX MXPA04001848A patent/MXPA04001848A/es unknown
- 2002-08-28 CA CA002458855A patent/CA2458855A1/en not_active Abandoned
- 2002-08-28 IL IL16055802A patent/IL160558A0/xx unknown
- 2002-08-28 WO PCT/FR2002/002945 patent/WO2003018060A1/fr not_active Ceased
- 2002-08-28 EP EP02774886A patent/EP1423146A1/fr not_active Ceased
-
2004
- 2004-02-25 US US10/786,483 patent/US7105504B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003018060A1 (fr) | 2003-03-06 |
| EP1423146A1 (fr) | 2004-06-02 |
| US7105504B2 (en) | 2006-09-12 |
| JP2005505539A (ja) | 2005-02-24 |
| FR2829027A1 (fr) | 2003-03-07 |
| MXPA04001848A (es) | 2004-06-15 |
| IL160558A0 (en) | 2004-07-25 |
| US20050107356A1 (en) | 2005-05-19 |
| CA2458855A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036302A1 (es) | Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion en el tratamiento de la enfermedad de parkinson | |
| TW200637614A (en) | Bendamustine pharmaceutical compositions | |
| GEP20217285B (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
| ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
| CY1113108T1 (el) | Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου | |
| BRPI0413318B8 (pt) | comprimido à prova de abuso termicamente formado sem extrusão | |
| EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
| CL2009001212A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras. | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| MXPA05009015A (es) | Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos. | |
| UY30711A1 (es) | Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.- | |
| ECSP056019A (es) | 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune | |
| CL2011000124A1 (es) | Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| CR7432A (es) | Amidas sustituidas activas del receptor de canabinoide-1 | |
| MXPA04001848A (es) | Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. | |
| PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
| GT201100127A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| MX2009000900A (es) | Derivados de imidazolonas sustituidas, preparacion y usos. | |
| CL2008002506A1 (es) | Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer. | |
| AR051904A1 (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r) | |
| MY149854A (en) | Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
| UY28736A1 (es) | Derivados de quinazolina | |
| IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |